Liquid Biopsy-Based Metabolomics in Epithelial Ovarian Cancer: Challenges, Methodological Advances and Translational Considerations
Diagnostics · 25.06.2026 · 16 (13) · 1983
DOI: 10.3390/diagnostics16131983 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 25.06.2026. Verfasst von Mariagrazia D'Agostino und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biosciences, Biotechnologies and Environment, University of Bari Aldo Moro, Via Orabona 4, 70125 Bari, Italy. Die Arbeit nennt 178 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Association for Cancer Research.
Abstract (Originalsprache)
Epithelial ovarian cancers (EOCs) histotypes are characterized by marked molecular heterogeneity and limited effectiveness of current screening and monitoring strategies. Earlier identification of tumor-associated alterations may support timely intervention, especially in genetically predisposed or early-onset patient populations. While liquid biopsy approaches have primarily focused on circulating DNA, RNA, and proteins, increasing evidence indicates that cancer-associated metabolic reprogramming generates measurable informative signals in peripheral biofluids. This review summarizes recent progress in liquid biopsy-derived metabolomics in EOCs, covering analytical platforms applied to serum, plasma, urine, and ascites. Recurrent metabolic signatures linked to tumor burden, disease stage, treatment response, and clinical outcome are described, and their significance in discriminating malignant and non-malignant conditions is critically discussed. Collectively, these findings suggest that metabolomics may provide complementary functional information alongside genomic and histopathological profiling. Although its clinical implementation still requires further validation and methodological standardization, ongoing advances in analytical technologies and the integration of high-dimensional metabolic data into machine learning-based frameworks may progressively support the identification of early tumor-associated alterations and contribute to more accurate disease stratification and biologically informed clinical management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biosciences, Biotechnologies and Environment, University of Bari Aldo Moro, Via Orabona 4, 70125 Bari, Italy.
- Department of Experimental Medicine, University of Salento, Via per Monteroni, 73100 Lecce, Italy.
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy.
- Gynecologic Oncology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, 70124 Bari, Italy.
- Department of Interdisciplinary Medicine, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy.
ORCID-Profile: Mariagrazia D'Agostino, Luna Laera, Martina Lanza, Monica Montopoli, Clelia Tiziana Storlazzi, Gennaro Cormio, Stefano Miglietta
Förderung
- Italian Association for Cancer Research
Zitieren
APA
D'Agostino, M., Laera, L., Lanza, M., Tolomeo, D., Montopoli, M., Storlazzi, C. T., Cormio, G., Castegna, A., & Miglietta, S. (2026). Liquid Biopsy-Based Metabolomics in Epithelial Ovarian Cancer: Challenges, Methodological Advances and Translational Considerations. Diagnostics, 16(13), 1983. https://doi.org/10.3390/diagnostics16131983
Vancouver
D'Agostino M, Laera L, Lanza M, Tolomeo D, Montopoli M, Storlazzi CT, et al. Liquid Biopsy-Based Metabolomics in Epithelial Ovarian Cancer: Challenges, Methodological Advances and Translational Considerations. Diagnostics. 2026;16(13):1983. doi:10.3390/diagnostics16131983
BibTeX
@article{DAgostino2026,
author = {D'Agostino, Mariagrazia and Laera, Luna and Lanza, Martina and Tolomeo, Doron and Montopoli, Monica and Storlazzi, Clelia Tiziana and Cormio, Gennaro and Castegna, Alessandra and Miglietta, Stefano},
title = {Liquid Biopsy-Based Metabolomics in Epithelial Ovarian Cancer: Challenges, Methodological Advances and Translational Considerations},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {13},
pages = {1983},
doi = {10.3390/diagnostics16131983}
}
EUVIMED